Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-PluReceptor NK Cells + Epcoritamab + Tafasitamab in R/R B-cell Non-Hodgkin Lymphoma
NCT07283679Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- Sep 2031
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label trial of ONC-PluReceptor NK cells in B-cell non-Hodgkin lymphoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Recommended Phase II Dose at 1 year. Started Feb 2026; status: recruiting.
02
Drugs
ONC-PluReceptor NK cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07283679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283679.